Mulroy Michael H.
SEC Form 4 insider trading activity
Mulroy Michael H. has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Nov 19, 2026.
On the most recent filing, Mulroy Michael H. is listed as Director at Lineage Cell Therapeutics, Inc. Inside the rolling window, Mulroy Michael H. reported 1 open-market purchase totaling $26K in LCTX and no open-market sales.
Companies traded
Other insiders at LCTX
Insider Buying
$26K
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Mulroy Michael H. made?
Mulroy Michael H. has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Mulroy Michael H. trade?
Mulroy Michael H. has filed SEC Form 4 disclosures for 1 company, including LCTX.
When was Mulroy Michael H.'s most recent SEC Form 4 filing?
Mulroy Michael H.'s most recent SEC Form 4 filing on Tracefour is dated Nov 19, 2026.
What is Mulroy Michael H.'s total buy and sell value in the current window?
Inside the rolling retention window, Mulroy Michael H. bought $26K and sold $0 based on SEC Form 4 filings.
What was Mulroy Michael H.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 30,000 LCTX shares on 2026-11-17, worth $26K, per SEC Form 4 filings.